PolyPid Insider Purchase Signals Confidence Ahead of FDA Review
PolyPid insider buy by COO Warshavsky Ori signals confidence in its surgical‑infection antibiotic pipeline; investors should watch FDA moves for potential upside.
3 minutes to read
PolyPid Ltd
PolyPid’s Equity Incentive Filing Signals Future Dilution & Investor Insights
PolyPid’s latest Form 3 shows Dror‑Darwish Nir’s unexercised stock‑option holdings and the company’s use of equity incentives, highlighting potential future dilution while maintaining investor confidence in its antibiotic pipeline and incremental gr…
3 minutes to read
PolyPid’s Insider Moves Boost Confidence Ahead of 2026 FDA Approval of D‑PLEX100
PolyPid’s insider buying and FDA waiver for D‑PLEX100 signal a strong 2026–29 growth push, positioning its novel β‑lactam/β‑lactamase combo to curb AMR and unlock valuation upside.
3 minutes to read